FORM 3

Flagship V VentureLabs Rx Fund, L.P.

(Middle)

(First)

(Last)

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden hours per response: 0.5

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	or	Section 30(n)	or the investment Compa	ny Act C	JI 1940				
1. Name and Address of Reporting Person*  Flagship Ventures Fund V  General Partner LLC		e of Event ing Statement n/Day/Year) /2021	3. Issuer Name and Ticker or Trading Symbol Sana Biotechnology, Inc. [ SANA ]						
(Last) (First) (Middle)			Relationship of Reporting Person(s) to Issuer (Check all applicable)				5. If Amendment, Date of Original Filed (Month/Day/Year)		
55 CAMBRIDGE PARKWAY SUITE 800E		Director X 10% Owner  Officer (give title below) Other (specify below)			6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting				
(Street) CAMBRIDGE MA 02142							:	Person  X Form filed Reporting	l by More than One Person
(City) (State) (Zip)									
	Table I - I	Non-Deriva	ative Securities Be	nefic	ially O	wned			
1. Title of Security (Instr. 4)		Beneficially Owned (Instr. Form:		Indirect					
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)									
Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Jnderlying Derivative Security Instr. 4)		4. Conversior or Exercise Price of			6. Nature of Indirect Beneficial Ownership (Instr. 5)	
	Date Exercisable	Expiration Date	Title		nount or Derivation Imber of Security		ve	or Indirect (I) (Instr. 5)	
Series A-2 Convertible Preferred Stock	(1)	(2)	Common Stock	1,48	7,371	(1)		I	See Footnotes <sup>(3)(7)</sup> (8)
Series A-2 Convertible Preferred Stock	(1)	(2)	Common Stock	9,72	5,122	(1)		I	See Footnotes <sup>(4)(7)</sup> (8)
Series A-2 Convertible Preferred Stock	(1)	(2)	Common Stock	11,44	11,326	(1)		I	See Footnotes <sup>(5)(7)</sup> (8)
Series A-2 Convertible Preferred Stock	(1)	(2)	Common Stock	11,58	35,199	(1)		I	See Footnotes <sup>(6)(7)</sup> (8)
1. Name and Address of Reporting Person Flagship Ventures Fund V C LLC		<u>rtner</u>							
(Last) (First) 55 CAMBRIDGE PARKWAY SUITE 800E	(Middle)								
(Street) CAMBRIDGE MA	02142								
(City) (State)	(Zip)								
1. Name and Address of Reporting Perso	on <sup>*</sup>								

Street)		
CAMBRIDGE	MA	02142
(City)	(State)	(Zip)
Name and Addrese Flagship Ven	_	
(Last) 55 CAMBRIDG	(First) E PARKWA	(Middle) Y, SUITE 800E
Street) CAMBRIDGE	MA	02142
(City)	(State)	(Zip)
. Name and Addre Flagship Pior	_	
(Last) 55 CAMBRIDG	(First)	(Middle) Y, SUITE 800E
Street) CAMBRIDGE	MA	02142
(City)	(State)	(Zip)
. Name and Addre Flagship Pior Partner LLC		Person* nd VI General
(Last) 55 CAMBRIDG	(First)	(Middle) Y, SUITE 800E
Street) CAMBRIDGE	MA	02142
(City)	(State)	(Zip)
. Name and Addre <u>Flagship Pior</u>		
(Last)	(First)	(Middle)
(Last) 55 CAMBRIDG	, ,	
	E PARKWA	
55 CAMBRIDG  Street)	E PARKWA	Y, SUITE 800E
Street) CAMBRIDGE City) . Name and Address	MA  (State)  ss of Reporting	Y, SUITE 800E 02142 (Zip)
Street) CAMBRIDGE City)  Name and Addres Flagship Ven Last)	MA  (State) ss of Reporting tureLabs \( (First) \)	Y, SUITE 800E  02142  (Zip)  Person* / Manager LLC  (Middle)
Street) CAMBRIDGE City)  Name and Address	MA  (State)  ss of Reporting tureLabs \( \)  (First)  E PARKWA	Y, SUITE 800E  02142  (Zip)  Person* / Manager LLC  (Middle)

1. Name and Address of Reporting Person* Flagship VentureLabs V LLC						
(Last) 55 CAMBRIDG	(First) EE PARKWAY, SU	(Middle) JITE 800E				
(Street) CAMBRIDGE	MA	02142				
(City)	(State)	(Zip)				
1. Name and Address of Reporting Person* <u>AFEYAN NOUBAR</u>						
(Last)	(First)	(Middle)				
55 CAMBRIDGE PARKWAY, SUITE 800E						
(Street) CAMBRIDGE	MA	02142				
(City)	(State)	(Zip)				

## **Explanation of Responses:**

- 1. The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering.
- 2. The expiration date is not relevant to the conversion of these securities.
- 3. Represents shares held directly by Flagship V VentureLabs Rx Fund, L.P. ("Flagship Fund V Rx").
- 4. Represents shares held directly by Flagship Pioneering Fund VI, L.P. ("Flagship Pioneering VI").
- 5. Represents shares held directly by Flagship VentureLabs V LLC. ("VentureLabs V").
- 6. Represents shares held directly by Flagship Ventures Fund V, L.P. ("Flagship Fund V" and together with Flagship Fund V Rx, Flagship Pioneering VI, VentureLabs V, the "Flagship Pioneering Funds").
- 7. VentureLabs V Manager LLC ("VentureLabs V Manager") is the manager of VentureLabs V. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of VentureLabs V Manager. The General Partner of Flagship Pioneering VI is Flagship Pioneering Fund VI General Partner LLC ("Flagship Pioneering VI GP"). The manager of Flagship Pioneering VI GP is Flagship Pioneering. The General Partner of Flagship Fund V and Flagship Fund V Rx is Flagship Ventures Fund V General Partner LLC ("Flagship V GP" and, together with VentureLabs V Manager, Flagship Pioneering, and Flagship Pioneering VI GP, the "Flagship General Partners").
- 8. (Continued from footnote 7) Noubar B. Afeyan, Ph.D. is the sole Director of Flagship Pioneering and may be deemed to have sole voting and investment control over all the shares held by VentureLabs V and Flagship Fund VI. In addition, Noubar B. Afeyan, Ph.D. serves as the sole manager of Flagship V GP and may be deemed to possess sole voting and investment control over all the shares held by Flagship Fund V and Flagship Fund V Rx. None of the Flagship General Partners nor Noubar B. Afeyan, Ph.D. directly own any of the shares held by the Flagship Pioneering Funds, and each of the Flagship General Partners and Dr. Noubar Afeyan, Ph.D. disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

## Remarks:

/s/ Flagship Ventures Fund V General Partner LLC, By: Noubar B. Afeyan, Title: Manager	02/03/2021
/s/ Flagship V VentureLabs Rx Fund, L.P., By: Flagship Ventures Fund V General Partner LLC, its General Partner, By: Noubar B. Afeyan, Title: Manager	02/03/2021
/s/ Flagship Ventures Fund V, L.P., By: Flagship Ventures Fund V General Partner LLC, its General Partner, By: Noubar B. Afeyan, Title: Manager	02/03/2021
/s/ Flagship Pioneering, Inc., By: Noubar B. Afeyan, Title: Director	02/03/2021
/s/ Flagship Pioneering Fund VI General Partner LLC, By: Flagship Pioneering, Inc., its Manager, By: Noubar B. Afeyan, Title: Director	02/03/2021

02/03/2021 /s/ Flagship Pioneering Fund VI, L.P., By: Flagship Pioneering Fund VI General Partner LLC, its General Partner, By: Flagship Pioneering, Inc., its Manager, By: Noubar B. Afeyan, Title: Director /s/ Flagship VentureLabs V Manager LLC, By: Flagship Pioneering, Inc., 02/03/2021 its Manager, By: Noubar B. Afeyan, Title: Director /s/ Flagship VentureLabs V LLC., By: Flagship VentureLabs V Manager LLC its Manager, By: 02/03/2021 Flagship Pioneering, Inc., its Manager, By: Noubar B. Afeyan, Title: Director /s/ Noubar B. Afeyan, Name: Noubar B. Afeyan, 02/03/2021 Ph.D.

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB

<sup>\*</sup> If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).